Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11660292-B2
Publication Date
2023-05-30
Expiration Date
Abstract
Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.
Core Innovation
The disclosure relates to an immediate release pharmaceutical composition comprising rifaximin and HPMC-AS. The composition comprises from about 16 wt % to about 18 wt % rifaximin and from about 16 wt % to about 18 wt % HPMC-AS.
The total amount of rifaximin in the immediate release pharmaceutical composition is 40 mg. The immediate release pharmaceutical composition is formulated for pharmaceutical use as a tablet.
Claims Coverage
The partial content contains one independent claim, covering a specifically defined immediate release rifaximin/HPMC-AS composition with a defined total rifaximin amount.
Immediate release composition with defined rifaximin and HPMC-AS amounts
An immediate release pharmaceutical composition comprising from about 16 wt % to about 18 wt % rifaximin and from about 16 wt % to about 18 wt % HPMC-AS, wherein the total amount of rifaximin is 40 mg.
Tablet formulation
The immediate release pharmaceutical composition of the defined rifaximin/HPMC-AS formulation is formulated as a tablet.
Overall, the claim coverage is limited to an immediate release pharmaceutical composition defined by wt % ranges of rifaximin and HPMC-AS and a total rifaximin amount of 40 mg, with further refinement to a tablet dosage form.
Stated Advantages
Documented Applications
Early decompensated cirrhosis with ascites, with clinical evaluation using Kaplan–Meier/time-to-event endpoints for hospitalization due to HE/EVB/SBP/HRS and/or all-cause mortality, and for time to development of medically refractory ascites.
Interested in licensing this patent?